Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 42

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 42
---
-looking statements in deciding how your vote should be cast or in voting your Denali Ordinary Shares on the Proposals. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in “ Risk Factors,” those discussed and identified in public filings made with the SEC by Denali and the following:

| • |     | our ability to complete the Business Combination with Semnur or, if we do not consummate such Business Combination, any other initial business combination; |

| • |     | satisfaction or waiver (if applicable) of the conditions to the consummation of the Business Combination, including the approval of the Merger Agreement by the shareholders of Denali; |

| • |     | the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; |

| • |     | the projected financial information, including Semnur’s forecasts (included in the section titled “Proposal 1 — The Business Combination Proposal — Certain Semnur Projected Financial Information”), anticipated growth rate, and market opportunity of New Semnur; |

| • |     | the ability to obtain and/or maintain the listing of New Semnur Common Stock on Nasdaq (or such other exchange as agreed by the parties, including the New York Stock Exchange (“NYSE”)) following the Business Combination; |

| • |     | New Semnur’s public securities’ potential liquidity and trading; |

| • |     | New Semnur’s ability to raise financing in the future; |

| • |     | New Semnur’s expected use of proceeds from future issuances of equity or convertible debt securities; |

6

| • |     | New Semnur’s future financial performance, including its revenue, costs of revenue and operating expenses; |

| • |     | the ability to realize the anticipated benefits of the Business Combination; |

| • |     | costs related to the Business Combination; |

| • |     | the outcome of any legal proceedings that may be instituted against Denali or Semnur related to the Business Combination; |

| • |     | the attraction and retention of qualified directors, officers, employees and key personnel of Denali and Semnur prior to the Business Combination, and New Semnur following the Business Combination; |

| • |     | the ability of Sem